{"id":10671,"date":"2019-11-11T11:25:52","date_gmt":"2019-11-11T10:25:52","guid":{"rendered":"https:\/\/udic.es\/?page_id=10671"},"modified":"2019-11-12T10:20:00","modified_gmt":"2019-11-12T09:20:00","slug":"projects-v1","status":"publish","type":"page","link":"https:\/\/udic.es\/en\/projects-v1\/","title":{"rendered":"Projects V1"},"content":{"rendered":"\t\t\t\t\t\n<h1>Lines of investigation.<\/h1>\n<h4>Active clinical trials<\/h4>\n\t\t\t\t<div class=\"sep\"><\/div>\t\n<div class=\"slogan clearfix  has-button\">\n\t<div class=\"slogan-content\">\n\t\t\n<h1>&#8220;\u00bfYou want to participate in our studies?&#8221;<\/h1>\n\t<\/div>\n\t\t<div class=\"button-wrp\">\n\t\t<a href=\"https:\/\/udic.es\/en\/contact\/\" class=\"button vamtam-button accent2  button-filled hover-accent1 \"><span class='icon shortcode  ' style=''>&#57935;<\/span><span class=\"btext\">Explain us<\/span><\/a>\t<\/div>\n\t<\/div>\n\n<div class=\"row \"><div class=\"wpv-grid grid-1-2  wpv-first-level first unextended animation-fade-in animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-83a735822df4e30f92b44c064eaf97cc\" >\t\t<div class=\"sep-text single centered\">\n\t\t\t\t\t\t\t<span class=\"sep-text-before\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t\t<div class=\"content\">\n\t\t\t\t<h2 class=\"text-divider-double\">Clinical trials at PARKINSON<\/h2>\t\t\t<\/div>\n\t\t\t<span class=\"sep-text-after\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t<\/div>\n\t<div class=\"wpv-accordion-wrapper wpv-accordion-1\"><style scoped>.wpv-accordion-1 .tab .inner { background-color: #5887b9; color: #ffffff; }<\/style><ul class=\"wpv-accordion\" data-collapsible=\"true\"><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">P2B001-003. Phase III trial of PHARMA TWO 2. A new idea: a capsule that combines low doses of rasagiline and pramipexole (two drugs already sold separately) in the initial Parkinson&#8217;s. It is intended to maintain or improve the efficacy of the two compounds or reduce the possible side effects (drowsiness, edema in the legs, impulse control disorder).<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p class=\"p1\"><span class=\"s1\"><b>\u2013 PHARMA TWO 2:<\/b> P2B001-003. A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson\u2019s Disease and to a Calibration Arm of Pramipexole ER. 2018. IP. Hospital Universitari General de Catalunya.<\/span><\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">CTH-302. SUNOVION phase III test. A practical and democratic solution for treating motor blockages in advanced Parkinson&#8217;s disease. Comparing the use on demand (according to the patient&#8217;s blockages) of a new sublingual apomorphine formulation. There has already been subcutaneous apomorphine for many years, but its administration by subcutaneous injection or by perfusion pump has limited its use. This clinical trial compares the 2 drugs and evaluates their efficacy and safety<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p><strong>\u2013 SUNOVION: CTH-302.<\/strong> An Open- Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson\u2019s Disease Complicated by Motor Fluctuations. 2018. IP. Hospital Universitari General de Catalunya. Fase III.<\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">AMBLED: PXT-CL17-001. Assaig de fase IIa de Prexton \/ Lundbeck de breu durada i recerca de diferents dosis. Una aportaci\u00f3 original en un greu problema cl\u00ednic sense una f\u00e0cil soluci\u00f3: les discin\u00e8sies. S&#8217; avalua un modulador glutamat\u00e8rgic front a placedo, per con\u00e8ixer la seva seguretat i la seva efic\u00e0cia en dicinesias coreicas invalidants.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p><strong>\u2013 PREXTON: PXT-CL17-001. AMBLED.<\/strong> A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 in Reducing Motor Complications of Levodopa Therapy in Parkinson\u2019s Disease Patients Experiencing End-of-Dose Wearing Off and Levodopa-Induced Dyskinesia. 2017-2018. IP. Hospital Universitari General de Catalunya.<\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">Open label extension sudy with sublingual apomorphine to assess its long-term safety (for 3 years). It offers a practical solution for its timely use, at the patient&#8217;s discretion, of motor blockages, without interfering with the rest of the patient&#8217;s usual medication.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p><strong>\u2013 SUNOVION: CTH-301:<\/strong> A phase 3, open-label study, examining the safety, tolerability and long-term efficacy of APL-130277 in patients with a response to levodopa with Parkinson\u2019s disease complicated by motor fluctuations (\u201cOFF\u201d episodes).<\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">CONTERA: JM010-CS03. An imaginative combination in a serious clinical problem: abnormal movements and dyskinesias. The efficacy and safety of Zolmitriptan and Bupropion, both at low doses, are studied in this complication of advanced Parkinson&#8217;s disease.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p><strong>-CONTERA: JM010-CS03.<\/strong> Randomized, double-blind, placebo-controlled study of parallel groups in patients with Parkinson&#8217;s disease with moderate to severe dyskinesia to assess the efficacy and safety and tolerability of two dose combinations of JM-010.<\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">IPX203-B16-02 (RISE-PD): A new formulation of Levodopa in Parkinson&#8217;s disease with motor Off periods, such as nocturnal akinesia. It is compared against standard Levodopa-Carbidopa. Similar to Rytary (Levodopa extended release) but with simultaneous acute effect. There is an open label extension period with a drug delivery for patients during 3 years.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p class=\"p1\"><span class=\"s1\"><strong>&#8211; IMPAX: IPX203-B16-02 (RISE-PD).<\/strong> Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release Carbidopa-Levodopa in Parkinson\u2019s Disease Patients with Motor Fluctuations.<\/span><\/div><\/div>\n\t\t\t\t\t<\/li><\/ul><\/div><\/div>\n<div class=\"wpv-grid grid-1-2  wpv-first-level unextended animation-fade-in animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-343b82da7b41b836b03bd31259a63fce\" >\t\t<div class=\"sep-text single centered\">\n\t\t\t\t\t\t\t<span class=\"sep-text-before\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t\t<div class=\"content\">\n\t\t\t\t<h2 class=\"text-divider-double\">Clinical trials at ALZHEIMER'S<\/h2>\t\t\t<\/div>\n\t\t\t<span class=\"sep-text-after\"><div class=\"sep-text-line\"><\/div><\/span>\n\t\t\t\t\t<\/div>\n\t<div class=\"wpv-accordion-wrapper wpv-accordion-2\"><style scoped>.wpv-accordion-2 .tab .inner { background-color: #5887b9; color: #ffffff; }<\/style><ul class=\"wpv-accordion\" data-collapsible=\"true\"><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">EISAI: BAN2401-G000-301 (CLARITY AD). An opportunity in the treatment of Alzheimer&#8217;s: monoclonal antiamyloid antibody to assess risk \/ benefit in reducing clinical worsening and amyloid burden. A phase III clinical trial that attempts to replicate the positive outcome of its phase II.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p class=\"p1\"><span class=\"s1\"><b>EISAI: BAN2401-G000-301 (CLARITY AD).<\/b> A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phaseto ConfirmSafety and Efficacy of BAN2401 in Subjects With Early Alzheimer\u2019s Disease<\/span><br \/><\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">Roche: WN29922 (GRADUATE). A reference essay. An anti-amyloid monoclonal antibody administered subcutaneously, which could replicate the positive result of the EMERGE trial, with Aducanumab from Biogen. In this case, Gantenereumab is compared to placebo, in order to evaluate the efficacy (in various neuropsychological like Clinical Dementia Rating) and the safety (with periodic controls in cerebral MRi) of increasing doses of this drug. An extended long-term extension is planned.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p><strong>-Roche: WN29922 (GRADUATE).<\/strong> A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Gantenerumab in patients with early (prodromal to mild) Alzheimer\u2019s disease<\/div><\/div>\n\t\t\t\t\t<\/li><li class=\"pane-wrapper\" style=\"\">\n\t\t\t\t\t<h4 class=\"tab\"><span class=\"inner\">A surprising hypothesis and an imaginative solution: a clinical trial to assess the efficacy and safety of a drug (administered orally) that could inhibit the proteases of a gum bacterium (P. gingivalis) that has been detected in the brain of patients with Alzheimer&#8217;s disease. It is an approach to this pathology, absolutely different from the other projects under way.<\/span><\/h4>\n\t\t\t\t\t<div class=\"pane\"><div class=\"inner\"><p class=\"p1\"><span class=\"s1\"><b>\u2013 CORTEXYME: OR388-010 (GAIN):<\/b> A Randomized, Double-Blind, Placebo-Controlled Study of COR388HCI in Subjects with Alzheimer\u2019s Disease. Phase II\/III<\/span><\/div><\/div>\n\t\t\t\t\t<\/li><\/ul><\/div><\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-2  wpv-first-level first unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-f1203548d9d48bed9e84e6e0d05b3196\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode theme ' style='font-size:60px !important;color:#3695EB;'>&#57565;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tParkinson's disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<p class=\"p1\"><span class=\"s1\"><strong>-SPARK: 228PD201.<\/strong> Phase II trial of Biogen. A disruptive therapy in the treatment of early Parkinson&#8217;s disease. The use of an anti-alfasinuclein monoclonal antibody against a placebo group allows the evaluation of the clinical response and the possible side effects of a new drug that aims to modify the natural history of the disease<br \/>\n<\/span><em><span style=\"color: #000080;\">BIOGEN: 228PD201. SPARK. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB037 in Subjects with Early Symptomatic Alzheimer\u2019s Disease. Fase III. 2018. IP. Hospital Universitari General de Catalunya.<\/span><\/em><\/p>\n<p class=\"p1\"><span class=\"s1\"><strong>-PASADENA: BP39529.<\/strong> A Boche phase II test. A disruptive therapeutic approach in the treatment of initial Parkinson&#8217;s disease. The monthly intravenous administration of an anti-alfasinuclein monoclonal antibody, compared to a placebo group, allows to evaluate the clinical efficacy and safety of a drug that could modify the natural history of this disease.<br \/>\n<\/span><em><span style=\"color: #000080;\">ROCHE: BP39529. PASADENA: A randomized, double-blind, placebo controlled, 52-week Phase II study to evaluate the efficacy of intravenous RO7046015 (PRX002) in participants with early Parkinson\u2019s disease with a 52-week blinded extension\u201d Fase II. 2018. IP. Hospital Universitari General de Catalunya.<\/span><\/em><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div>\n<div class=\"wpv-grid grid-1-2  wpv-first-level unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-a3338f23cb47d23395c5b2f0980eb437\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode theme ' style='font-size:60px !important;color:#3695EB;'>&#57529;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tAlzheimer's disease.\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<p class=\"p1\"><span class=\"s1\"><b>EISAI: BAN2401-G000-201 OLE. <\/b><\/span><span class=\"s1\">The option to benefit from a positive result (less clinical worsening and severe reduction of amyloid load) in a phase II Alzheimer&#8217;s with monoclonal antiamiolide therapy, only for those patients who participated in this trial.<br \/>\n<\/span><em><span style=\"color: #000080;\">EISAI: BAN2401-G000-201 OLE. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study with an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer\u2019s Disease<\/span><\/em><\/p>\n<p class=\"p1\"><span class=\"s1\"> <\/span><\/p>\n<p><div id=\"attachment_8528\" style=\"width: 5066px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-8528\" class=\"size-full wp-image-8528\" src=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\" alt=\"\" width=\"5056\" height=\"1752\" srcset=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg 5056w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-300x104.jpg 300w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-768x266.jpg 768w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-1024x355.jpg 1024w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-1140x395.jpg 1140w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-555x192.jpg 555w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-360x125.jpg 360w, https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros-262x91.jpg 262w\" sizes=\"auto, (max-width: 5056px) 100vw, 5056px\" \/><\/a><p id=\"caption-attachment-8528\" class=\"wp-caption-text\">Udic<\/p><\/div><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-2  wpv-first-level first unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-6b52b0c6ed8de0d752b37fd2feda2d78\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode theme ' style='font-size:60px !important;color:#3695EB;'>&#57529;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tProgressive Supranuclear Paralysis\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 UCB: PSP003<\/strong>. A Participant-Blind, Investigatir Blind, Placebo-Controlled, Phase IB Study to evaluate the safety, tolerability, and pharmacokinetics of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).<\/p>\n<p><strong>\u2013 BIOGEN: <\/strong><b>251PP301 (PASSPORT).<\/b> A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy. Phase III.  2017. Principal Investigator E. Balaguer. Hospital Universitari General de Catalunya, Sant Cugat.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div>\n<div class=\"wpv-grid grid-1-2  wpv-first-level unextended animation-from-left animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-f8d8be4b690adf16f4528d884d8efbc0\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode theme ' style='font-size:60px !important;color:#3695EB;'>&#57529;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tArriving soon...\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>&#8211; UCB: PSP001.<\/strong> A Double-Blind, Placebo-Controlled, Phase III Study to evaluate the efficacy and safety, of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).<\/p>\n<p><strong>&#8211; <b>IMPAX: <\/b>IPX203-B16-03.<\/strong> An Open Label Extension to Compare the Safety and Efficacy of IPX203 with Immediate-Release Carbidopa-Levodopa in Parkinson\u2019s Disease Patients with Motor Fluctuations.<\/p>\n<p class=\"p4\"><span class=\"s3\"><strong>&#8211; <b>BIOGEN: 254PD101 (REASON).<\/b><\/strong> <\/span><span class=\"s4\"><b> <\/b><\/span><span class=\"s2\">A Phase 1 Single and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults with Parkinson\u2019s Disease.<\/span><\/p>\n<p class=\"p1\"><span class=\"s1\"><strong>&#8211; <b>TauRx Therapeutics: TRx-237-039 (LUCIDITY).<\/b><\/strong> A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 9 Month, Brain Imagin and S&amp;E Study of LMTM in Subjects with Early Alzheimer&#8217;s Disease.<\/span><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n\t\t<h2 class=\"text-divider-double\">\t\t\t\nHistory of clinical trials\t\t<\/h2>\t\t<div class=\"sep\"><\/div>\t\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-15de64eff7f8f6b86db61a31faf927bc\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57588;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tParkinson's disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<span class=\"s2\"><b>\u2013 INTEC PHARMA:<\/b> IN11004 y IN11004E: Estudio en fase III, multic\u00e9ntrico, aleatorizado, con doble enmascaramiento, con doble simulaci\u00f3n, con control activo, para comparar la eficacia y la seguridad del comprimido de retenci\u00f3n g\u00e1strica y liberaci\u00f3n controlada (<\/span><span class=\"s3\"><i>accordion pills<\/i><\/span><span class=\"s2\">) carbidopa\/levodopa (AP-CD\/LD) y CD\/LD de liberaci\u00f3n inmediata en pacientes con enfermedad de Parkinson fluctuante. 2016-2018. IP. Hospital Universitari General de Catalunya.<\/span><\/p>\n<p><strong>&#8211; BIOTIE\/ACORDA:<\/strong> TOZ CL-05. <em>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson\u2019s Disease Experiencing End-of-Dose \u201cWearing-Off<\/em>. 2016-2018. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; CIVITAS\/ACORDA:<\/strong> CVT-301-004 <em>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson\u2019s Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD\u2122).<\/em> 2016-20174.IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; CIVITAS\/ACORDA:<\/strong> CVT 301-005. Estudio randomizado para investigar la seguridad y el efecto de CVT301 (Levodopa inhalada) comparada con el tratamiento est\u00e1ndar de la enfermedad de Parkinson con fluctuaciones motoras (off). 2015-2016. IP. Hospital Universitari General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; OSMOTICA:<\/strong> ALLAYD-II. OS320-3006. Ensayo multic\u00e9ntrico, randomizado, controlado con placebo, doble ciego, para evaluar eficacia y seguridad de amantadina \u201c<em>extended release<\/em>\u201d, durante 26 semanas, en enfermedad de Parkinson con discinesias inducidas por levodopa. 2015-2016. IP. Hospital Universitari General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; OSMOTICA:<\/strong> ALLAYD-I. OS320-3005. Ensayo multic\u00e9ntrico, randomizado, controlado con placebo, doble ciego, para evaluar eficacia y seguridad de amantadina \u201c<em>extended release<\/em>\u201d, durante 16 semanas, en enfermedad de Parkinson con discinesias inducidas por levodopa. 2015-2016. IP. Hospital Universitari General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; BIAL:<\/strong> BIA 91067-301.Estudio en Fase III: Eficacia y Seguridad de BIA 91067-301 en pacientes con enfermedad de Parkinson Idiop\u00e1tica con fen\u00f3meno de <em>Wearing Off <\/em>tratados con Levodopa y un inhibidor de Dopa decarboxilasa (IDDC): Ensayo Cl\u00ednico Multic\u00e9ntrico, doble ciego, aleatorizado controlado con placebo y activo, de grupos paralelos. 2011-2014. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; MUNDIPHARMA:<\/strong> OXN 2504. Estudio en Fase III, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia y la tolerabilidad de OXN PR para el tratamiento del dolor intenso asociado con la enfermedad de Parkinson. 2012-2013. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CAFQ056 A2299. Estudio en Fase II\/III de tratamiento abierto para evaluar la seguridad, tolerabilidad y eficacia de AFQ056 en las discinesias inducidas por levodopa en pacientes con enfermedad de Parkinson. 2012-2013. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CAFQ056 A2223. Estudio en Fase II doble ciego, controlado con placebo, de dosis fija, multic\u00e9ntrico, de 13 semanas de seguimiento para evaluar la eficacia y seguridad de la liberaci\u00f3n modificada de AFQ056 en la reducci\u00f3n de las discinesias inducidas por levodopa, moderadas a graves, en pacientes con enfermedad de Parkinson. 2012-2013. IP Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CAFQ056 A2222. Estudio en Fase II, doble ciego, controlado con placebo, de dosis fija, multic\u00e9ntrico, de 12 semanas de seguimiento para evaluar la eficacia y seguridad de AFQ056 en la reducci\u00f3n de las discinesias inducidas por levodopa, moderadas a graves, en pacientes con enfermedad de Parkinson. 2012-2013. IP Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; MERCK SCHERING PLOUGH:<\/strong> P05664. Estudio de eficacia y seguridad de fase 3, doble ciego, controlado con placebo y tratamiento activo, de b\u00fasqueda del intervalo de dosis del Preladenant en sujetos con enfermedad de Parkinson inicial. 2011-2013. IP. Hospital General de Catalunya. IP: Dr. A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa.<\/p>\n<p><strong>&#8211; MERCK SCHERING PLOUGH:<\/strong> P06153. Estudio en Fase III de extensi\u00f3n controlado con tratamiento activo, doble ciego y doble simulaci\u00f3n del Preladenant en sujetos con enfermedad de Parkinson de moderado a grave. 2011-2013. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; MERCK SCHERING PLOUGH:<\/strong> P04938. Estudio de eficacia y seguridad de fase 3, doble ciego, controlado con placebo y tratamiento activo, de 12 semanas de duraci\u00f3n, sobre el Preladenant en sujetos con enfermedad de Parkinson de moderada a grave. 2011-2013. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; SCHWARZ BIOSCIENCES (UCB):<\/strong> SP1066. <em>A multicenter, randomized, double-blind, two-way cross-over study to compare the adhesiveness of two different Rotigotine patch formulations in subjects with Parkinson\u2019s disease. <\/em>2011-2013. IP. Hospital General de Catalunya. Fase I.<\/p>\n<p><strong>&#8211; MERCK SERONO:<\/strong> OLE28850<strong>. <\/strong>Estudio en Fase III abierto para determinar la seguridad a largo plazo de Safinamida en Pacientes con Enfermedad de Parkinson. 2012-2014. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; MERCK SERONO:<\/strong> EMR 701165-024. Estudio de Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognici\u00f3n, en pacientes no dementes con enfermedad de Parkinson (EP) idiop\u00e1tica y deterioro cognitivo. 2010-2013. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; IMPAX Pharmaceuticals:<\/strong> IPX066-B09-03. Estudio para evaluar la seguridad y eficacia de IPX066 en la enfermedad de Parkinson avanzada. Extensi\u00f3n en abierto. 2010-2011. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; IMPAX Pharmaceuticals:<\/strong> IPX066-B09-02. Estudio para evaluar la seguridad y eficacia de IPX066 en la enfermedad de Parkinson avanzada EudraCT 2009-014688-37. 2010. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CAFQ056A2208. Estudio Multic\u00e9ntrico, doble ciego, placebo control, con dosis fija, de 13 semanas, para evaluar la eficacia y seguridad de AFQQ056 en la reducci\u00f3n de las discinesias moderadas y severas inducidas por Levodopa, en pacientes con Enfermedad de Parkinson. 2009-2010. IP. Hospital General de Catalunya. Fase IIb.<\/p>\n<p><strong>&#8211; ACADIA:<\/strong> ACP-103-014. <em>A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson\u2019s Disease<\/em>. 2008-2009. IP. Hospital General de Catalunya. Fase IIb.<\/p>\n<p><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> BI 248.634. <em>Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson\u2019s disease (PD)<\/em>. 2008-2009. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> BI 248.525. Estudio aleatorizado, doble ciego, doble ocultaci\u00f3n, controlado con placebo, de 3 grupos paralelos para comparar la eficacia, seguridad y tolerabilidad de Pramipexol ER frente a placebo y frente a Pramipexol IR, administrados por v\u00eda oral durante una fase de mantenimiento de 26 semanas en pacientes con enfermedad de Parkinson avanzada tratados con Levodopa. 2007-2008.IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; GSK:<\/strong> RO105323. Ensayo cl\u00ednico para evaluar eficacia y seguridad de Pramipexol retard versus Pramipexol standard y placebo en enfermedad de Parkinson avanzada con fluctuaciones motoras y discinesias. 2006-2007. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; SCHWARZ PHARMA:<\/strong> SP 873. Ensayo cl\u00ednico, internacional, \u201c<em>proof of concept<\/em>\u201d, para evaluar eficacia y seguridad de Rotigotina, administrada por v\u00eda intranasal en enfermedad de Parkinson avanzada con fluctuaciones motoras y discinesias. 2006. IP. Hospital General de Catalunya. Fase IIa.<\/p>\n<p><strong>&#8211; SCHWARZ PHARMA:<\/strong> SP 833. Ensayo cl\u00ednico de extensi\u00f3n en abierto, multic\u00e9ntrico, para evaluar eficacia, tolerancia y seguridad de Rotigotina, administrada en parches subcut\u00e1neos, en pacientes con enfermedad de Parkinson inicial y trastornos del sue\u00f1o. 2005-2006. IP. Fase III.<\/p>\n<p><strong>&#8211; SCHWARZ PHARMA:<\/strong> SP 825. Ensayo cl\u00ednico, multic\u00e9ntrico, aleatorizado, controlado con Ropinirol, para evaluar eficacia, tolerancia y seguridad de Rotigotina, administrada en parches subcut\u00e1neos, en pacientes con enfermedad de Parkinson inicial y trastornos del sue\u00f1o. 2005. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; SCHWARZ PHARMA:<\/strong> SP 516. Ensayo cl\u00ednico de extensi\u00f3n en abierto, multic\u00e9ntrico, para evaluar eficacia, tolerancia y seguridad de Rotigotina, administrada en parches subcut\u00e1neos, en pacientes con enfermedad de Parkinson avanzada. 2004-2006. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; SCHWARZ PHARMA:<\/strong> SP 515. Ensayo cl\u00ednico, multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo y Pramipexol, para evaluar eficacia, tolerancia y seguridad de Rotigotina, administrada en parches subcut\u00e1neos, en pacientes con enfermedad de Parkinson avanzada. 2003-2005. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CENA 713-IA 05. Estudio prospectivo, multic\u00e9ntrico, randomizado, doble ciego, controlado con placebo y con grupos paralelos, de 24 semanas de duraci\u00f3n, para comprobar la eficacia, tolerabilidad y seguridad de 3-12 mg\/d\u00eda de Exelon (Rivastigmina) en c\u00e1psulas, en pacientes con demencia vascular probable. Abril 2003-2005. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CENA 713-B2311 E1. Estudio de extensi\u00f3n de tratamiento abierto de 24 semanas de duraci\u00f3n del ensayo cl\u00ednico: Estudio multic\u00e9ntrico, prospectivo, aleatorizado, doble ciego, paralelo y placebo controlado, de 24 semanas de duraci\u00f3n, para evaluar la eficacia, tolerabilidad y seguridad de 3-12 mg\/d\u00eda de Exelon (Rivastigmina) en c\u00e1psulas, en pacientes con demencia debida a Enfermedad de Parkinson. 2003-2005. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CENA 713-B2311. Estudio multic\u00e9ntrico, prospectivo, aleatorizado, doble ciego, paralelo y placebo controlado, de 24 semanas de duraci\u00f3n, para evaluar la eficacia, tolerabilidad y seguridad de 3-12 mg\/d\u00eda de Exelon (Rivastigmina) en c\u00e1psulas, en pacientes con demencia debida a Enfermedad de Parkinson. 2002-2004. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CCOM998 IA04. Estudio multic\u00e9ntrico y abierto para evaluar distintos reg\u00edmenes de dosis de la combinaci\u00f3n levodopa \/ DDCI \/ entacapona, en pacientes con enfermedad de Parkinson que empiezan a experimentar s\u00edntomas de deterioro de final de dosis. 2001. IP. Hospital General de Catalunya. Fase IV.<\/p>\n<p><strong>&#8211; SCHERING AG:<\/strong> Administraci\u00f3n subcut\u00e1nea continua (12h\/24h) en enfermedad de Parkinson avanzada con fluctuaciones complejas y discinesias, mediante bomba de infusi\u00f3n subcut\u00e1nea de Lisuride. 1987-1988. Investigador colaborador. Investigador principal: Dr. E. Tolosa. Hospital Cl\u00ednic (Barcelona). Fase II <em>(proof of concept).<\/em><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-d5c172e4bfb43002a6d06e5cb0a5d629\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57578;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tAlzheimer's disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>\u2013 ACADIA:<\/strong> ACP-103-045. A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis. Principal Investigator E. Balaguer. Hospital Universitari General de Catalunya, Sant Cugat.<\/p>\n<p><strong>&#8211; BIOGEN:<\/strong> 221AD205 (EVOLVE). Phase 2 , Multicenter, Randomized, Paralell-Group, Double- Blind, Controlled Study of Aducanumab (BIIB037) in Subjects with Mild Cognitive Impairment due to Alzheimer\u2019s Disease and Mild Alzheimer\u2019s Dementia to Evaluate the Safety of Continued Dosing in Subjects with Asymptomatic Amyloid-Related Imaging Abormalities (ARIA). Fase II. 2019. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> 1346.23 <em>A multi-centre, double-blind, parallel-group, randomized controlled study to investigate efficacy, safety and tolerability of orally administered BI 425809 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer\u2019s Disease<\/em>.2018-2019. IP. Hospital Universitari General de Catalunya. IP: Dr. Antonio Hern\u00e1ndez. Hospital Sant Joan de D\u00e9u, Manresa. Fase II.<\/p>\n<p><strong>&#8211; EISAI<\/strong><strong>:<\/strong> E2609-G000-301 (MISSION AD). <em>A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer\u2019s Disease<\/em>. 2017-2018. IP. Hospital Universitari General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; HEPTARES.<\/strong> HTL0018318-202. <em>A phase 1b randomized, double-blind, placebo-controlled, parallel group, multi-center study to determine the safety and tolerability of HTL0018318 in subjects with mild to moderate Alzheimer\u2019s disease receiving donepezil or donepezil \/ memantine<\/em>. 2017-2018. Hospital Universitari General de Catalunya. Fase I b.<\/p>\n<p><strong>&#8211; JANSSEN:<\/strong> 54861911ALZ2003 (EARLY). <em>A phase II b \/ III randomized, double-blind, placebo-controlled, parallel group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risc for developing Alzheimer\u2019s Dementia.<\/em> 2016-2017. IP: Dr. A. Ugarte. IP 2017-2018. Hospital Sant Joan de D\u00e9u, Manresa.<\/p>\n<p><strong>&#8211; AXOVANT:<\/strong> RVT-101-3002. <em>Open Label extension of a phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer\u2019s disease<\/em>. 2017. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; AXOVANT:<\/strong> RVT-101-3001. <em>A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer\u2019s disease.<\/em> 2016-2018. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; ROCHE:<\/strong> BN40031 (CREAD OLE). Estudio multic\u00e9ntrico, abierto, de extensi\u00f3n a largo plazo de los estudios de Fase III (BN29552\/BN29553) de Crenezumab (RO5490245) en pacientes con enfermedad de Alzheimer de car\u00e1cter leve<strong>. <\/strong>2018-2019. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; ROCHE:<\/strong> BN 29553 (CREAD2). Estudio de fase III, multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos, para evaluar la eficacia y seguridad de Crenezumab (RO5490245) en pacientes con enfermedad de Alzheimer de car\u00e1cter leve<strong>.<\/strong> 2018-2019. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; ROCHE:<\/strong> BN 29552 (CREAD). Estudio de fase III, multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos, para evaluar la eficacia y seguridad de Crenezumab (RO5490245) en pacientes con enfermedad de Alzheimer de car\u00e1cter leve<strong>.<\/strong> 2017-2019. IP. Hospital Universitari General de Catalunya.<\/p>\n<p><strong>&#8211; BIOGEN:<\/strong> 221AD301 (EMERGE). Estudio de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de Aducanumab (BIIB037) en pacientes con enfermedad de Alzheimer temprana\u201d. IP: Dr. A. Ugarte. IP 2016-2017. IP. 2017-2019. Hospital Sant Joan de D\u00e9u, Manresa.<\/p>\n<p><strong>&#8211; LILLY<\/strong> \/ ASTRAZENECA: I8D-MC-AZET (DAYBREAK). Estudio aleatorizado, doble ciego, controlado con placebo y de comienzo aplazado de LY3314814 \/ AZD3293 en la demencia de la enfermedad de Alzheimer leve. Fase III.2017-2018. IP. Hospital Universitari General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; ASTRAZENECA \/ LILLY:<\/strong> AZD3293 (AMARANTH). Estudio multic\u00e9ntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de 24 meses de duraci\u00f3n, sobre la eficacia, seguridad, tolerabilidad, biomarcadores y farmacocin\u00e9tica de AZD3293 \/ LY3314814 en la enfermedad de Alzheimer en fase inicial. 2015-2017. IP: Dr. A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa. IP. 2017-2019. Fase II\/III.<\/p>\n<p><strong>&#8211; BOEHRINGER INGELHEIM:<\/strong> 1289.5. Estudio multic\u00e9ntrico, doble ciego, aleatorizado controlado de grupos paralelos para investigar la eficacia, seguridad y tolerabilidad de BI 409306, administrado oralmente durante un periodo de tratamiento de 12 semanas, comparado con placebo en pacientes con enfermedad de Alzheimer. 2015-2016. IP. Hospital Universitari General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; LILLY:<\/strong> H8A-MC-LZAX. Efecto de la inmunizaci\u00f3n pasiva en la progresi\u00f3n de la enfermedad de Alzheimer leve de Solanezumab (LY2062430) frente a placebo. Fase III. 2014-2015. IP: Dr. A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa.<\/p>\n<p><strong>&#8211; GRIFOLS:<\/strong> IG1002 (AMBAR). Estudio multic\u00e9ntrico, aleatorizado y controlado para evaluar la eficacia y seguridad del recambio plasm\u00e1tico a corto plazo seguido de plasmaf\u00e9resis a largo plazo con infusiones de alb\u00famina humana combinada con inmunoglobulina intravenosa en pacientes con enfermedad de Alzheimer leve- moderada. 2014-2015. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; LUNDBECK:<\/strong> LU14863. Estudio cl\u00ednico de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego, comparativo, controlado con placebo y con grupos paralelos, para evaluar la eficacia y seguridad de Lu AE58054 en pacientes con enfermedad de Alzheimer de car\u00e1cter leve moderado y tratados con inhibidores de la acetilcolinesterasa. 2015-2016. IP. Dr. A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa. IP. Hospital General de Catalunya.<\/p>\n<p><strong>&#8211; LUNDBECK:<\/strong> LU14861B \/ Memantina. Extensi\u00f3n en abierto y con Memantina del ensayo 14861A. 2015-2016.Investigador colaborador. IP: Dr. A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; LUNDBECK:<\/strong> LU14861A. Estudio aleatorizado, doble ciego, degrupos paralelos y controlado con placebo, de dosis fijas de Lu AE 58054 en pacientes con enfermedad de Alzheimer leve o moderada, tratados con Donepezilo. 2014-2015. IP: Dr. A. Ugarte. Hospital Sant Joan de D\u00e9u, Manresa. IP. Hospital General de Catalunya. Fase III.<\/p>\n<p><strong>&#8211; LUPIN:<\/strong> LRP\/LND101001. <em>A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer\u2019s Disease<\/em>. 2013-2015. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; EISAI:<\/strong> BAN2401-G000-201. Estudio de pauta posol\u00f3gica controlado con placebo, doble ciego, con grupos paralelos y con dise\u00f1o bayesiano de aleatorizaci\u00f3n adaptativa, para evaluar la seguridad, tolerabilidad y eficacia de BAN2401 en sujetos con enfermedad de Alzheimer incipiente. 2013-2017. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; SERVIER:<\/strong> CL2-38093-012<strong>.<\/strong> Estudio en Fase IIb, multic\u00e9ntrico, aleatorizado para investigar la eficacia y seguridad de 3 dosis de S38093 (2, 5 y 20 mg\/d\u00eda) frente a placebo, asociado a Donezepilo (10 mg\/d\u00eda) en pacientes con enfermedad de Alzheimer moderada. 2013-2015. IP. Hospital General de Catalunya. Fase IIb.<\/p>\n<p><strong>&#8211; ROCHE:<\/strong> BP 28248. Estudio en Fase III, multic\u00e9ntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para investigar la eficacia y seguridad de RO4602522 a\u00f1adido al tratamiento de base con los inhibidores de la acetilcolinesterasa, Donezepilo o Rivastigmina, en pacientes con enfermedad de Alzheimer de intensidad moderada. 2013-2015. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; GENENTECH:<\/strong> GN 28525. Estudio de extensi\u00f3n en abierto para evaluar la eficacia y la seguridad de MABT5102A en pacientes con enfermedad de Alzheimer leve o moderada. 2013-2016. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; LILLY:<\/strong> 140-MC-BACC. Evaluaci\u00f3n de la seguridad, la tolerabilidad y los efectos farmacodin\u00e1micos de LY2886721 en pacientes con deterioro cognitivo leve debido a la enfermedad de Alzheimer o con enfermedad de Alzheimer leve. 2013. IP. Hospital General de Catalunya. Fase Ib\/ II.<\/p>\n<p><strong>&#8211; GENENTECH (ROCHE)<\/strong><strong>:<\/strong> GN ABE 4869g. Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad MABT5102A en pacientes con enfermedad de Alzheimer leve a moderada. 2011-2013. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CAD106 A2203. Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo, de 90 semanas de duraci\u00f3n y con dise\u00f1o adaptativo en pacientes con enfermedad de Alzheimer leve para investigar la seguridad, tolerabilidad y respuesta de anticuerpos espec\u00edficos anti-AB despu\u00e9s de la administraci\u00f3n intramuscular repetida de CAD106 con adyuvante. 2010-2015. IP. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; GSK:<\/strong> AVA 105640. <em>A 36-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE \u03b54-stratified subjects with mild to moderate Alzheimer\u2019s disease<\/em>. 2006. IP: Dr. L. Soler Singla. Hospital General de Catalunya. Fase II.<\/p>\n<p><strong>&#8211; NOVARTIS:<\/strong> CENA 713-ES-02. Estudio piloto, multic\u00e9ntrico, aleatorizado, doble ciego, controlado, paralelo, para evaluar la eficacia y seguridad de Rivastigmina frente a placebo en el tratamiento de los s\u00edntomas cognitivos y no cognitivos de pacientes con enfermedad de Alzheimer moderada-grave. 2001-2003. IP. Hospital General de Catalunya. Fase II.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-c98710695ff9669c02f011c659321d5f\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57603;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tProgressive Supranuclear Paralysis\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>&#8211; Alfa Bioresearch:<\/strong> AB 13004. <em>A prospective, multicenter, randomised, double-blind, placebo-controlled, parallels groups fase IIb \/ III study to compare the efficacy and safety of Masitinib versus placebo in the treatment of patients suffereing from Progressive Supranuclear Palsy<\/em>. Fase IIb\/III. 2016-2017. IP.<\/p>\n<p><strong>&#8211; BRISTOL MYERS SQUIB \/ BIOGEN.<\/strong> CN 002-012 \/ 251PP301. Ensayo PASSPORT. Ensayo aleatorizado, doble ciego, placebo-control, de grupos paralelos para evaluar la eficacia y seguridad de BMS 986168 administrado intravenosamente en pacientes con Par\u00e1lisis Supranuclear Progresiva con una extensi\u00f3n en abierto. Fase III. 2017-2018. IP<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-ea55ebd82fff1b4f71b8b4cff4138042\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57607;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tX fragile syndrome\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<span lang=\"ES\"><strong>&#8211; NOVARTIS: <\/strong>CAFQ056 A2212.Estudio doble ciego, randomizado, controlado por placebo y de grupos paralelos para evaluar la eficacia y seguridad de AFQ056 en pacientes adultos con S\u00edndrome de Fr\u00e1gil. Fase II, Noviembre 2011-2013. IP.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; NOVARTIS:<\/strong> CAFQ056 B2214. Estudio doble ciego, randomizado, controlado por placebo y de grupos paralelos para evaluar la eficacia y seguridad de AFQ056 en pacientes adolescentes con S\u00edndrome de Fr\u00e1gil. Fase II, Febrero 2012-2013. IP.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; NOVARTIS:<\/strong> CAFQ056 B2279. Estudio de extensi\u00f3n de tratamiento abierto para evaluar la seguridad, eficacia y tolerabilidad de AFQ056 en pacientes adultos con S\u00edndrome de X Fr\u00e1gil. Fase II, Marzo 2012-2013. IP.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; NOVARTIS: <\/strong>CAFQ056 B2278. Estudio de extensi\u00f3n de tratamiento abierto para evaluar la seguridad, y tolerabilidad de AFQ056 en pacientes adolescentes con S\u00edndrome de X Fr\u00e1gil. Fase II, Junio 2012-2013. IP.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; NOVARTIS:<\/strong>periodos para evaluar la farmacocin\u00e9tica, seguridad y tolerabilidad de una dosis \u00fanica oral y de dosis m\u00faltiples orales de AFQ056 en pacientes con SXF entre 5 y 11 a\u00f1os de edad (Cohorte 1) y entre 3 y 4 a\u00f1os de edad (Cohorte 2). Fase I. 2012. IP.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; ROCHE: <\/strong>NP27936.Estudio en Fase II, aleatorizado, doble ciego y de grupos paralelos controlado con placebo para investigar la eficacia y la seguridad de RO4917523 en pacientes con S\u00edndrome de X Fr\u00e1gil. Fase II, Noviembre 2012. IP.<\/span><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-bdc28fc75e8145b50a8f16fee1afc07e\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57602;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tMultiple sclerosis\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<span lang=\"ES\"><strong>&#8211; NURON:<\/strong> NU-100-101. Estudio en Fase III multic\u00e9ntrico, doble ciego, aleatorizado, controlado con placebo y con grupos paralelos para evaluar la seguridad y la eficacia de NU100 en pacientes con formas recidivantes de esclerosis m\u00faltiple. Agosto 2012. IP. Investigador colaborador en Hospital Sant Joan de D\u00e9u, Manresa, Fundaci\u00f3 Althaia<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; NOVARTIS:<\/strong> CFTY 720 D2402. Estudio Fase II, doble ciego, aleatorizado, doble ciego, multicentrico de grupos paralelos que estudia los cambios estructurales en la retina y la evoluci\u00f3n de la funci\u00f3n visual despu\u00e9s del tratamiento inmediato frente al retardado con fingolimod en pacientes con neuritis \u00f3ptica desmelianizante aguda. Junio 2013. IP<\/span><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-40822a99cd5afe15d405041d01f09e5e\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57592;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tEpilepsy\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>&#8211; BIAL:<\/strong> Estudio epidemiol\u00f3gico de la depresi\u00f3n en pacientes con epilepsia focal y su impacto en la calidad de vida. Estudio IMDYVA (IMpacto de la Depresi\u00f3n Y calidad de VidA). Fase IV. 2012. Investigador colaborador.<\/p>\n<p><strong>&#8211; BIAL:<\/strong> BIA 2093-311. Eficacia y Seguridad del Acetato de Eslicarbazepina (BIA 2-093) como monoterapia para pacientes con nuevo diagn\u00f3stico de crisis de comienzo parcial: Estudio doble ciego, aleatorizado, comparado con f\u00e1rmaco activo, de grupos paralelos y multic\u00e9ntrico. Fase III. Abril 2012-2017. IP en Hospital General de Catalunya. Investigador colaborador en Hospital Sant Joan de D\u00e9u, Manresa, Fundaci\u00f3 Althaia. IP: Dr A. Ugarte. IP desde Septiembre de 2017.<\/p>\n<p><strong>&#8211; UCB:<\/strong> SP 0980. Eficacia y Seguridad de Lacosamida en epilepsia f\u00e1rmaco-resistente. Fase III. Abril 2012. Investigador colaborador. Hospital Sant Joan de D\u00e9u, Manresa, Fundaci\u00f3 Althaia IP: Dr. Antonio Ugarte.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-2e4d039e10ffd0ce7fe571b658da6f1c\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tNon-neurological Clinical Trials\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>&#8211; LEON FARMA:<\/strong> CF 111\/302. Estudio de Fase III pivotal, multic\u00e9ntrico, doble ciego, doble enmascarado, aleatorizado, para comparar la eficacia contraceptiva, tolerabilidad y seguridad de LF111 (Drospirenona) durante 9 ciclos con Cerazette (Desogestrel 0,075 mg). Noviembre 2012- Junio 2013.Investigador colaborador y gesti\u00f3n. 2013.<\/p>\n<p><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> A randomized, double-blind, parallel-arm, Phase I study to evaluate pharmacokinetics and pharmacodynamics of BI 695500 vs. rituximab (MabThera\u00ae) induction immunotherapy as first line treatment in patients with low tumor burden follicular lymphoma. 2013. Fase I. Investigador colaborador y gesti\u00f3n.Investigador colaborador y gesti\u00f3n. 2013.<\/p>\n<p><strong>&#8211; NOVARTIS. PERSPECTIVE.<\/strong> CLCZ696B2320. Estudio multic\u00e9ntrico, aleatorizado, doble ciego, controlado con tratamiento activo, para evaluar los efectos de LCZ696 comparado con Valsartan en la funci\u00f3n cognitiva en pacientes con insuficiencia cardiaca cr\u00f3nica y fracci\u00f3n de eyecci\u00f3n preservada. Fase III.2017-2018. IP.<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-1476cb13fcc17e7af828f431a5888f33\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tcerebrovascular disease\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<span lang=\"ES\"><strong>&#8211; ASTRA:<\/strong> CLASS (Clometiazol Acute Stroke Study). Neuroprotecci\u00f3n con clometiazol, doble ciego, placebo-control, en ictus agudo, de 6 a 12 horas de evoluci\u00f3n. Fase II. 1996-1997. Investigador colaborador. IP: Dr. L. Soler Singla.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; URIACH:<\/strong> TACIP. Trifusal versus \u00e1cido acetilsalic\u00edlico en la prevenci\u00f3n secundaria del ictus isqu\u00e9mico. Fase IV. 1997-1998. Investigador colaborador. IP: Dr. L. Soler Singla.<\/span><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-d95f5e035381e0606bf0b9f09df4b556\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tRestless Leg Syndrome\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<span lang=\"ES\"><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> BI 248.604. Estudio aleatorizado para evaluar eficacia y seguridad de Pramipexol versus placebo en s\u00edndrome de piernas inquietas y alteraci\u00f3n del estado de \u00e1nimo. Fase III. Enero\u2013Junio 2007. IP.<\/span><\/p>\n<p><span lang=\"ES\"><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> BI 248.615. Estudio aleatorizado para evaluar eficacia y seguridad de Pramipexol versus placebo en s\u00edndrome de piernas inquietas y alteraci\u00f3n del sue\u00f1o. Fase III. Enero\u2013Junio 2007. IP.<\/span><\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"row \"><div class=\"wpv-grid grid-1-1  wpv-first-level first unextended animation-from-right animated-active\" style=\"padding-top:0px;padding-bottom:0px\" id=\"wpv-column-bf8e0f44acf06ed4b902a504dbd382b6\" ><div class=\"services clearfix fullimage no-image has-icon no-button \" style=\"text-align:left;\">\n\t<div class=\"services-inside\">\n\t\t\t\t\t\t\t\t\t<div class=\"thumbnail\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class='icon shortcode  ' style='font-size:60px !important;color:#3695EB;'>&#57586;<\/span>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"sep-2\"><\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h3 class=\"services-title\">\n\t\t\t\t\t\t\t\t\tTourette syndrome\t\t\t\t\t\t\t<\/h3>\n\t\t\t\t\t\t\t<div class=\"services-content\">\n<strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> BI 248.641. A Phase III double-blind, double-dummy, placebo-controlled, 8-week fixed-dose trial with pramipexole IR (Mirapex\u00ae, Mirapexin\u00ae, Pexola\u00ae, Sifrol\u00ae) 0.125 and 0.5 mg\/day administered orally to investigate the efficacy and safety in patients 6-17 years of age diagnosed with Tourette Syndrome according to DSM-IV criteria. Fase III. 2009. IP.<\/p>\n<p><strong>&#8211; BOEHRINGER-INGELHEIM:<\/strong> BI 248.642. An open-label, flexible dose, follow-upstudy to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg\/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Tourette Syndrome according to DSM-IV criteria and who have completed the double-blind phase of either study 248.641 or 248.644. Fase III. 2009. IP.<\/p>\n<p><strong>&#8211; OTSUKA:<\/strong> 31-12-293. Estudio multic\u00e9ntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la eficacia del aripiprazol administrado en dosis fijas por v\u00eda oral una vez al d\u00eda en ni\u00f1os y adolescentes con s\u00edndrome de Gilles de la Tourette. Fase III. 2013. IP.<\/p>\n<p><strong>&#8211; OTSUKA:<\/strong> 31-12-294. Estudio cl\u00ednico multic\u00e9ntrico, abierto para evaluar la seguridad y la tolerabilidad del aripiprazol administrado por v\u00eda oral una vez al d\u00eda a ni\u00f1os y adolescentes con el s\u00edndrome de Gilles de la Tourette. Fase III. 2013. IP<\/div>\n\t\t\t\t\t<\/div>\n<\/div>\n<\/div><\/div>\n<div class=\"push\" style='height:30px'><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-10671","page","type-page","status-publish"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Projects V1 - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/projects-v1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Projects V1 - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/projects-v1\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:modified_time\" content=\"2019-11-12T09:20:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"30 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/projects-v1\/\",\"url\":\"https:\/\/udic.es\/en\/projects-v1\/\",\"name\":\"Projects V1 - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/projects-v1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/projects-v1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\",\"datePublished\":\"2019-11-11T10:25:52+00:00\",\"dateModified\":\"2019-11-12T09:20:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/projects-v1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/projects-v1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/projects-v1\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/projects-v1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects V1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Projects V1 - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/projects-v1\/","og_locale":"en_US","og_type":"article","og_title":"Projects V1 - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_url":"https:\/\/udic.es\/en\/projects-v1\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_modified_time":"2019-11-12T09:20:00+00:00","og_image":[{"url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"30 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/projects-v1\/","url":"https:\/\/udic.es\/en\/projects-v1\/","name":"Projects V1 - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/projects-v1\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/projects-v1\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg","datePublished":"2019-11-11T10:25:52+00:00","dateModified":"2019-11-12T09:20:00+00:00","breadcrumb":{"@id":"https:\/\/udic.es\/en\/projects-v1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/projects-v1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/projects-v1\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/11\/Nosotros.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/projects-v1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"Projects V1"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages\/10671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=10671"}],"version-history":[{"count":25,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages\/10671\/revisions"}],"predecessor-version":[{"id":10750,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/pages\/10671\/revisions\/10750"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=10671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}